留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

特应性皮炎瘙痒机制及相关治疗研究进展

唐珏 姚志荣

唐珏, 姚志荣. 特应性皮炎瘙痒机制及相关治疗研究进展[J]. 协和医学杂志, 2022, 13(3): 473-479. doi: 10.12290/xhyxzz.2021-0747
引用本文: 唐珏, 姚志荣. 特应性皮炎瘙痒机制及相关治疗研究进展[J]. 协和医学杂志, 2022, 13(3): 473-479. doi: 10.12290/xhyxzz.2021-0747
TANG Jue, YAO Zhirong. Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 473-479. doi: 10.12290/xhyxzz.2021-0747
Citation: TANG Jue, YAO Zhirong. Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 473-479. doi: 10.12290/xhyxzz.2021-0747

特应性皮炎瘙痒机制及相关治疗研究进展

doi: 10.12290/xhyxzz.2021-0747
基金项目: 

国家自然科学基金 81874252

详细信息
    通讯作者:

    姚志荣, E-mail:yaozhirong@xinhuamed.com.cn

  • 中图分类号: R758.23

Research and Therapy Progress on the Mechanisms of Pruritus in Atopic Dermatitis

Funds: 

National Natural Science Foundation of China 81874252

More Information
  • 摘要: 特应性皮炎(atopic dermatitis, AD)是一种慢性复发性炎症性皮肤病, 慢性瘙痒是其特征性症状之一。AD瘙痒的发生机制复杂, 目前认为与皮肤屏障功能障碍、免疫调节异常及外界环境因素相关; 瘙痒-搔抓恶性循环可加重皮肤屏障的破坏、促进皮肤炎症反应及神经失调过程, 是AD瘙痒不易控制的原因之一。目前控制AD瘙痒的药物包括外用药物和系统药物, AD瘙痒机制的研究为其治疗提供了新靶点, 如IL-4、IL-13、IL-31、JAK、IL-33等。本文就AD瘙痒机制及相关治疗研究进展进行综述。
    作者贡献:唐珏负责查阅文献和撰写论文;姚志荣负责指导和修订论文。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  特应性皮炎瘙痒机制示意图

    KC:角质形成细胞;CGRP:降钙素基因相关肽;SP:P物质;Th2 cell: 2型辅助性T细胞;TRPV1:瞬时受体电位香草酸亚型1;IL:白细胞介素;CysLTR2:半胱氨酸白三烯受体2;LTC4:白三烯C4;H1R:H1受体;PAR2:激活蛋白酶活化受体2;TRPA1:瞬时受体电位锚蛋白1;TSLPR:胸腺基质淋巴细胞生成素受体;TSLP:胸腺基质淋巴细胞生成素;MrgprC11:Mas相关G蛋白偶联受体C11

  • [1] Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis[J]. Nat Rev Dis Primers, 2018, 4: 1.
    [2] Shaw TE, Currie GP, Koudelka CW, et al. Eczema pre-valence in the United States: data from the 2003 National Survey of Children's Health[J]. J Invest Dermatol, 2011, 131: 67-73. doi:  10.1038/jid.2010.251
    [3] Albrecht M, Dittrich AM. Expression and function of histamine and its receptors in atopic dermatitis[J]. Mol Cell Pediatr, 2015, 2: 16. doi:  10.1186/s40348-015-0027-1
    [4] Bataille A, Leschiera R, L'Hérondelle K, et al. In Vitro Differentiation of Human Skin-Derived Cells into Functional Sensory Neurons-Like[J]. Cells, 2020, 9: 1000. doi:  10.3390/cells9041000
    [5] Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1[J]. J Allergy Clin Immunol, 2014, 133: 448-460. doi:  10.1016/j.jaci.2013.10.048
    [6] Tsakok T, Woolf R, Smith CH, et al. Atopic dermatitis: the skin barrier and beyond[J]. Br J Dermatol, 2019, 180: 464-474. doi:  10.1111/bjd.16934
    [7] Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch[J]. Cell, 2017, 171: 217-228. e13. doi:  10.1016/j.cell.2017.08.006
    [8] Wilson SR, Thé L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013, 155: 285-295. doi:  10.1016/j.cell.2013.08.057
    [9] Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview[J]. Exp Dermatol, 2002, 11: 12-24. doi:  10.1034/j.1600-0625.2002.110102.x
    [10] Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. doi:  10.1016/j.cell.2020.12.033
    [11] Petersen LJ, Church MK, Skov PS. Platelet-activating factor induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade[J]. J Allergy Clin Immunol, 1997, 99: 640-647. doi:  10.1016/S0091-6749(97)70026-5
    [12] Tsagareli MG, Nozadze I, Tsiklauri N, et al. Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators: Respective Involvement of TRPV1 and TRPA1[J]. Neuroscience, 2020, 449: 35-45. doi:  10.1016/j.neuroscience.2020.09.048
    [13] McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519: 237-241. doi:  10.1038/nature14022
    [14] Chandran V, Coppola G, Nawabi H, et al. A Systems-Level Analysis of the Peripheral Nerve Intrinsic Axonal Growth Program[J]. Neuron, 2016, 89: 956-970. doi:  10.1016/j.neuron.2016.01.034
    [15] Zhang H, Guo Y, Wang W, et al. Mutations in the filaggrin gene in Han Chinese patients with atopic dermatitis[J]. Allergy, 2011, 66: 420-427. doi:  10.1111/j.1398-9995.2010.02493.x
    [16] Howell MD, Parker ML, Mustelin T, et al. Past, present, and future for biologic intervention in atopic dermatitis[J]. Allergy, 2015, 70: 887-896. doi:  10.1111/all.12632
    [17] Mack MR, Kim BS. The Itch-Scratch Cycle: A Neuroim-mune Perspective[J]. Trends Immunol, 2018, 39: 980-991. doi:  10.1016/j.it.2018.10.001
    [18] Uche LE, Gooris GS, Bouwstra JA, et al. Barrier Capability of Skin Lipid Models: Effect of Ceramides and Free Fatty Acid Composition[J]. Langmuir, 2019, 35: 15376-15388. doi:  10.1021/acs.langmuir.9b03029
    [19] Imai Y, Yasuda K, Nagai M, et al. IL-33-Induced Atopic Dermatitis-Like Inflammation in Mice Is Mediated by Group 2 Innate Lymphoid Cells in Concert with Basophils[J]. J Invest Dermatol, 2019, 139: 2185-2194. e3. doi:  10.1016/j.jid.2019.04.016
    [20] Smith L, Gatault S, Casals-Diaz L, et al. House dust mite-treated PAR2 over-expressor mouse: A novel model of atopic dermatitis[J]. Exp Dermatol, 2019, 28: 1298-1308. doi:  10.1111/exd.14030
    [21] Skabytska Y, Kaesler S, Volz T, et al. The role of innate immune signaling in the pathogenesis of atopic dermatitis and consequences for treatments[J]. Semin Immunopathol, 2016, 38: 29-43. doi:  10.1007/s00281-015-0544-y
    [22] Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progres-sive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis[J]. J Allergy Clin Immunol, 2012, 130: 1344-1354. doi:  10.1016/j.jaci.2012.07.012
    [23] Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs[J]. Allergy, 2020, 75: 1582-1605. doi:  10.1111/all.14318
    [24] Tsoi LC, Rodriguez E, Stölzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses[J]. J Allergy Clin Immunol, 2020, 145: 1406-1415. doi:  10.1016/j.jaci.2019.11.047
    [25] Imamachi N, Park GH, Lee H, et al. TRPV1-expressing primary afferents generate behavioral responses to pruritogens via multiple mechanisms[J]. Proc Natl Acad Sci USA, 2009, 106: 11330-11335. doi:  10.1073/pnas.0905605106
    [26] Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch[J]. Cell, 2021, 184: 422-440. e17. doi:  10.1016/j.cell.2020.12.033
    [27] Song S, Lee K, Lee YM, et al. Acute health effects of urban fine and ultrafine particles on children with atopic dermatitis[J]. Environ Res, 2011, 111: 394-399. doi:  10.1016/j.envres.2010.10.010
    [28] 中国医师协会皮肤科医师分会过敏性疾病专业委员会, 中华医学会皮肤性病学分会特应性皮炎研究中心, 中国医疗保健国际交流促进会皮肤科分会. 特应性皮炎瘙痒管理专家共识[J]. 中华皮肤科杂志, 2021, 54: 391-396.
    [29] Oyoshi MK, Larson RP, Ziegler SF, et al. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression[J]. J Allergy Clin Immunol, 2010, 126: 976-984. e9845. doi:  10.1016/j.jaci.2010.08.041
    [30] Howell MD, Novak N, Bieber T, et al. Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis[J]. J Invest Dermatol, 2005, 125: 738-745. doi:  10.1111/j.0022-202X.2005.23776.x
    [31] Hon KL, Tsang YC, Pong NH, et al. Patient acceptabi-lity, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema[J]. Hong Kong Med J, 2015, 21: 417-425.
    [32] Seo SR, Lee SG, Lee HJ, et al. Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis[J]. Acta Derm Venereol, 2017, 97: 957-958. doi:  10.2340/00015555-2699
    [33] Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines[J]. J Clin Psychopharmacol, 2002, 22: 511-515. doi:  10.1097/00004714-200210000-00012
    [34] Zhang X, Wu Z, Hayashi Y, et al. Peripheral role of cathepsin S in Th1 cell-dependent transition of nerve injury-induced acute pain to a chronic pain state[J]. J Neurosci, 2014, 34: 3013-3022. doi:  10.1523/JNEUROSCI.3681-13.2014
    [35] Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC-14028 cream-a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase Ⅱb randomized trial[J]. Br J Dermatol, 2019, 180: 1030-1038. doi:  10.1111/bjd.17455
    [36] Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults[J]. Dermatol Ther (Heidelb), 2017, 7: 493-505. doi:  10.1007/s13555-017-0201-6
    [37] Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic derma-titis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389: 2287-2303. doi:  10.1016/S0140-6736(17)31191-1
    [38] Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial[J]. JAMA Dermatol, 2020, 156: 44-56. doi:  10.1001/jamadermatol.2019.3336
    [39] 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020, 53: 81-88. https://www.cnki.com.cn/Article/CJFDTOTAL-LPFZ202005016.htm
    [40] Ruzicka T, Mihara R. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis[J]. N Engl J Med, 2017, 376: 2092-2093. doi:  10.1056/NEJMc1704013
    [41] Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis[J]. JAKSTAT, 2013, 2: e24137.
    [42] Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80: 913-921. e9. doi:  10.1016/j.jaad.2018.01.018
    [43] Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicen-tre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396: 255-266. doi:  10.1016/S0140-6736(20)30732-7
    [44] Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145: 877-884. doi:  10.1016/j.jaci.2019.11.025
    [45] Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies[J]. J Am Acad Dermatol, 2021, 85: 863-872. doi:  10.1016/j.jaad.2021.04.085
    [46] Ciaravino V, Coronado D, Lanphear C, et al. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis[J]. J Dermatol Sci, 2017, 87: 116-122. doi:  10.1016/j.jdermsci.2017.03.020
    [47] Chen YL, Gutowska-Owsiak D, Hardman CS, et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis[J]. Sci Transl Med, 2019, 11: eaax2945. doi:  10.1126/scitranslmed.aax2945
    [48] 黄世杰. 依托吉单抗治疗中重度特应性皮炎未能达到主终点[J]. 国际药学研究杂志, 2020, 47: 402. https://www.cnki.com.cn/Article/CJFDTOTAL-GWYZ202005014.htm
    [49] Simpson EL, Parnes JR, She D, et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial[J]. J Am Acad Dermatol, 2019, 80: 1013-1021. doi:  10.1016/j.jaad.2018.11.059
  • 加载中
图(1)
计量
  • 文章访问数:  138
  • HTML全文浏览量:  13
  • PDF下载量:  70
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-11-14
  • 录用日期:  2022-01-10
  • 网络出版日期:  2022-05-13
  • 刊出日期:  2022-05-30

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。